Icaritin/ZKAB-001

N/A

Report date: 2025/12/18 17:46:07

Base Information

Drug NameIcaritin/ZKAB-001
Drug Alias NameIcaritin/ZKAB-001STIA-1014/SNG-162Icaritin/STIA-1014SNG-162/STIA-1014STIA-1014/Icaritin +[9] 
ClassificationBiologics
Mechanisms of ActionProgrammed cell death protein 1 blockersEstrogen receptor alpha modulatorsMyeloid differentiation primary response protein MyD88 inhibitors +[9] 
TargetsEstrogen receptor alphaProgrammed cell death protein 1Myeloid differentiation primary response protein MyD88 +[6] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes IcaritinSocazolimab
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShenogen Pharma Group LtdLee’S Pharmaceutical Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLee’S Pharmaceutical Holdings LtdShenogen Pharma Group Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A